stockportfolio.pro
Stocks / CAI vs LGND
CAI vs LGND
Caris Life Sciences, Inc. and Ligand Pharmaceuticals Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Caris Life Sciences, Inc. (CAI) | Ligand Pharmaceuticals Incorporated (LGND) | |
|---|---|---|
| Market cap | $5.0B | $5.0B |
| Revenue (latest FY) | $812.03M | $268.09M |
| Net income (latest FY) | $-68.09M | $124.45M |
| Revenue growth (5y CAGR) | 46.5% | 10.4% |
| Net margin | -8.4% | 46.4% |
| Return on equity | -11.8% | 12.2% |
| P/E ratio | — | 32.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 6 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CAI — free Open LGND — freeFrequently asked questions
Which is bigger, CAI or LGND?
Ligand Pharmaceuticals Incorporated is larger by market capitalization — $5.0B versus $5.0B.
Which grows faster, CAI or LGND?
Over the last five fiscal years, Caris Life Sciences, Inc. grew revenue faster — 46.5%/yr versus 10.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.